FDAsafety guidance66% confidence
FDA AP — DEFLAZACORT (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Upsher Smith Labs; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA220709. Sponsor: CARNEGIE. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: DEFLAZACORT.
Supporting Context
- Therapeutic area
- Immunology · Corticosteroid
- Sub-indication
- General
Related signal: FDA Approves Deflazacort Supplement Application by Upsher Smith Labs